The spread of a single multi-drug resistant Plasmodium falciparum lineage to south Vietnam has caused alarm after worrying treatment failure rates. Researchers suggest this presents a serious concern for malaria control efforts.
Editor, Martha Powell, discusses the issues around the current guidance for treating HAT and gives an overview of the current clinical pipeline being spearheaded by the Drugs for Neglected Diseases initiative.
Maternal microchimerism (MMc) is a normal part of pregnancy, however, relatively little work has been done exploring the intersection of MMc and infectious disease. Here, Whitney Harrington discusses it’s implications in malaria.
Novel drug, AQ-13, has demonstrated promise against uncomplicated malaria in a Phase II non-inferiority trial, presenting a potential new tool for tackling drug-resistant strains.
Resistance to Naphthoquine has been found in mouse models and might emerge in future as widely used. In this article, the in vivo antimalarial activity of novel naphthoquine derivatives is assessed revealing promising antimalarial candidates for further research.
Researchers have developed a microfluidic device that can assess the deformability of red blood cells and consequently haemolytic anemia. In future it could be used to monitor the disease progression of malaria.
In the first large-scale study of malaria gene function researchers identified that the parasite has a high proportion of essential genes, and have identified potential new targets for antimalarial drugs.
Researchers have discovered that the malaria parasite actively adapts to host calorie intake, identifying a nutrient-sensing enzyme that modulates the pathogen’s replication rate and virulence.
In this review, the authors discuss recent findings on unfolded protein response (UPR) induction/modulation by intracellular parasites in host cells.
Researchers have discovered a variation in the human red blood cell receptor glycophorin that appears to reduce the risk of severe malaria by 40%.
